Clinical Trial Update: CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms [EARLY_Phase 1]

View source ↗

Summary

An early-phase study of CAR 70-BCMA CAR-T cells for relapsed or refractory plasma cell neoplasms, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CAR 70-BCMA CAR-T Cells

Snippet

Sponsor: The General Hospital of Western Theater Command | Conditions: Relapsed or Refractory Plasma Cell Neoplasms | EARLY_Phase 1 | Status: NOT_YET_RECRUITING